Tetra Radar · FDA Approvals · Decision date
veligrotug: FDA decision date
Viridian Therapeutics Inc. (VRDN) · 30 June 2026
We submitted a BLA for veligrotug to the FDA in October 2025, which was accepted for filing and granted Priority Review in December 2025 with a Prescription Drug User Free Act (“PDUFA”) target action date of June 30, 2026.
Source: 10-Q of 5 May 2026
The FDA approved it on 26 June 2026.
The FDA approved Lumvoa to treat thyroid eye disease.
Viridian Therapeutics Inc. on Tetra Radar
A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.